Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Clinical trial NCT06125834 · UNKNOWN
Trial details
- NCT number
- NCT06125834
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-01
- Primary completion
- 2025-04-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.